STOML2 stabilizes PARL and prevents gemcitabine-mediated PINK1-dependent mitophagy to reduce the chemoresistance of pancreatic cancer, making STOML2-targeted therapy as a potential strategy for gemcitabine sensitization (Qin et al., 2023). The gene discussed is STOML2; the disease is pancreatic neoplasm.